Skip to main content


Which Meds are Best for Acute Low Back Pain?

Feb 22, 2023

Acute low back pain (LBP) is a common cause of disability. An analysis in the Journal of Orthopaedic Research examined which non-opioid drugs are best for treating this condition.

The analysis, which included

Read Article

Heavy Metals and the Risk of Arthritis

Feb 21, 2023

The etiology of arthritis was studied using US National Health and Nutrition Examination Survey (NHANES) data and suggested that elevated concentrations of trace elements (TE: Pb, Cd, and Cu) were associated with increased risk of arthritis.

TE concentrations for whole blood [cadmium

Read Article

Half the Experts are Wrong (2.17.2023)

Feb 17, 2023

Dr. Jack Cush reviews the news and tries to stump the expert panel this week on the podcast.

Read Article
On Dec. 19, 2022, the U.S. Food & Drug Administration (FDA) approved subcutaneous abaloparatide (Tymlos) for the treatment of men with osteoporosis at high risk of fracture
Recent Cochrane review of Vit D, Calcium and OP shows no evidence to support the isolated or combined use of calcium & vit D in premenopausal women to improve BMD (hip or spine) or results in the prevention of fractures (vertebral and non‐vertebral).

Novel Proteomic Biomarker Set in Osteoarthritis

Feb 02, 2023

NIH funded researchers from Duke University have developed a set of serum proteomic biomarkers that successfully predict clinically relevant knee osteoarthritis (KOA) progression (both structural change and joint pain) over a 2 year period.

Read Article

Women at high risk of fracture remain untreated for osteoporosis

Jan 30, 2023

An estimated 100,000 to 120,000 fragility fractures occur annually in the Netherlands, the equivalent of at least 11 broken bones per hour. The cause is osteoporosis, a disease in which the skeleton becomes weak and fragile, leading to potentially devastating fractures that result in

Read Article

Blood Test Identifies Osteoarthritis Progression

Jan 25, 2023

A new blood test that can identify progression of osteoarthritis in the knee is more accurate than current methods, providing an important tool to advance research and speed discovery of new therapies.

The test relies on a biomarker and fills an important void in medical research for

Read Article

Burden of BMI on Costs of Musculoskeletal Diseases

Jan 23, 2023

A cross-sectional global study shows a substantial impact of obesity and BMI on the health and economic impact of patients with musculoskeletal (MSK) disorders.

In this cross-sectional study of 192 countries and territories, 7.3 million years lived with disability and $180.7 billion

Read Article

Poorer health outcomes for at-risk patients with fractures

Jan 18, 2023

People at high risk of fracture who also have complex or multiple chronic medical conditions are less likely to receive treatment for the underlying osteoporosis and also have poorer health outcomes, according to a new study from the Garvan Institute of Medical Research.  


Read Article
Evidence based Latin American Guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update

ACP Guidelines on Fracture Prevention in at-risk Adults

Jan 09, 2023

The American College of Physicians (ACP) has updated its 2017 recommendations on pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults. The full document and guideline can be found in the Annals of Internal Medicine. This guideline is the

Read Article
ACP Recommends Bisphosphonates as Initial Therapy for Osteoporosis The guideline is based on a systemic review and network meta-analysis conducted by the ACP Center for Evidence Reviews at the Portland Veteran Affairs Research Foundation.

ACP Recommends Bisphosphonates as Initial Therapy for Osteoporosis

Jan 03, 2023

The American College of Physicians (ACP) has issued an update of its guideline with clinical recommendations for treatments of primary osteoporosis and low bone mass in adults. In the new guideline, ACP recommends bisphosphonates as initial pharmacologic treatment to reduce the risk of

Read Article
Full read review of advances in bone biology leading to drug development (denosumab, romosuzumab, Burosumab), advances in Pagets and rickets and key regulatory molecules for bone remodeling, RANK, RANKL, OPG, & sclerostin

How Underweight Women Can Reduce Hip Fracture Risk

Nov 28, 2022

How women can reduce the risk of hip fracture?  

Read Article
Update on ACR Guideline on Prevention and Treatment of GIOP. Sequential Rx when initial OP Rx and GC discontinued Mary Beth Humphrey #ACR22 @RheumNow
Updated ACR Guidelines on Prevention and Rx of GIOP Rx recommendations when new fractures occur after 12 months of initial OP Rx Mary Beth Humphrey #ACR22 @RheumNow
#ACR22 #Osteoporosis Guidelines Case Example: The FRAX score needs to be adjusted (multiply by 1.15 or 1.2) in pts who are expected to have cumulative dose >5 grams/year of steroids @rheumnow
Dr. B Humphrey #ACR22 #Osteoporosis Guidelines: Treatment algorithms for GIO and in special populations (age < 18) @rheumnow
14M111 Updated ACR Guidelines for Glucocorticoid-Induced Osteoporosis #ACR22 🦴🦴 Initial Fracture Risk Assessment - by age - remember: no FRAX scores <40 yo Fracture re-assessments every 1-2 years with repeat BMD and risk stratifications @RheumNow
Dr. B Humphrey #ACR22 #Osteoporosis Guidelines: in patients under 40 yo, you cannot calculate #FRAX score, assess BMD and in children get also thoracolumbar xrays. Get repeat testing every 1-2 years #ACR22 @rheumnow
14M111 Updated ACR Guidelines for Glucocorticoid-Induced Osteoporosis #ACR22 🦴🦴 Reminder: Recalculate FRAX scores with scaling for prednisone equivalent dosing! Use other clinical fracture risk assessments @RheumNow
Staggering stats after a #osteoporosis hip fracture! 40% cannot walk independently 30% have a permanent disability 20% mortality in surgically fixed hip 40% mortality if not surgically fixed. -Dr. M Humphrey #ACR22 @rheumnow
ATOM study, Abs 1314, greater proportion of men with OP on abaloparatide vs placebo met the definition of a >3% responder at the LS, TH, and FN. #ACR22 @RheumNow